Background
==========

Interstitial lung disease (ILD) is characterized by interstitial inflammation of the lung and is frequently associated with collagen diseases, when it is designated collagen vascular disease-associated ILD (CVD-ILD). CVD-ILD is one of the major manifestations of collagen disease that influence the prognosis \[[@B1],[@B2]\]. Acute-onset diffuse ILD (AoDILD) occurs in patients with collagen disease with or without underlying CVD-ILD \[[@B3]\]. AoDILD includes acute exacerbation of ILD (AE-ILD), drug-induced ILD (DI-ILD), and *Pneumocystis* pneumonia. The prognosis of AoDILD is quite poor. AE-ILD is due to collagen diseases *per se* and characterized by pathological findings of diffuse alveolar damage overlapping with chronic fibrotic lung. DI-ILD occurs frequently in rheumatoid arthritis (RA) patients treated with methotrexate. *Pneumocystis* pneumonia is defined by the presence of *P. jirovecii* organisms in the respiratory tract. However, the classification of AoDILD is not established.

The roles of several cytokines, chemokines, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) were reported in idiopathic pulmonary fibrosis (IPF) and in acute respiratory distress syndrome (ARDS) \[[@B4]-[@B6]\]. Few studies have focused on AoDILD in collagen diseases. Therefore, we investigated the serum biomarker profile of AoDILD in collagen diseases in order to shed light on pathogenesis and markers informative for disease severity or predicting outcome.

Methods
=======

Patients and sera
-----------------

Twenty-five patients with collagen diseases (mean age ± standard deviation (SD): 65.9 ± 10.8 years; 11 men) were admitted to Sagamihara Hospital between 2001 and 2010, because of AoDILD requiring corticosteroid pulse therapy. AoDILD was defined as acute onset and progression within a month, the presence of clinical symptoms (fever, dry cough, or dyspnea), hypoxia, and computed tomography findings of ILD \[[@B3]\]. Patients with evidence of apparent bacterial infection or heart disease were excluded. These 25 collagen disease patients with AoDILD include 9 AE-ILD, 16 DI-ILD, and no *Pneumocystis* pneumonia. In this study, AoDILD was classified to AE-ILD, DI-ILD, and *Pneumocystis* pneumonia as following: *Pneumocystis* pneumonia was defined by the presence of *P. jirovecii* organisms detected by polymerase chain reaction for *P. jirovecii* or Grocott stain from bronchoalveolar lavage fluids or sputa of patients, DI-ILD was defined as AoDILD with treatment of DI-ILD causing drugs (disease-modifying anti-rheumatic drugs or immunosuppressants excluding corticosteroid) at onset after the exclusion of *Pneumocystis* pneumonia, AE-ILD was defined as AoDILD without treatment of DI-ILD causing drugs at onset, but with underlying CVD-ILD, after the exclusion of *Pneumocystis* pneumonia and DI-ILD. These 16 patients with DI-ILD were treated at onset with methotrexate (n = 10), gold sodium thiomalate (n = 1), tacrolimus (n = 2), cyclophosphamide (n = 1), or etanercept (n = 2). Sera were collected on admission, and in the stable state, at least three months before admission. They were classified according to the American College of Rheumatology criteria for RA \[[@B7]\], systemic sclerosis (SSc) \[[@B8]\], and Bohan's criteria for polymyositis/dermatomyositis (PM/DM) \[[@B9]\]. Diagnoses of the patients included 20 RA, 2 SSc, and 3 PM/DM. These 25 collagen disease patients with AoDILD include 11 patients who died and 14 who survived, during the course of AoDILD. The major cause of death of these 11 patients would be respiratory failure due to AoDILD, though the complication of infection due to repetitive corticosteroid pulse therapy could not be completely excluded. This study was reviewed and approved by Sagamihara Hospital Research Ethics Committee. Written informed consent was obtained from all study participants except those already deceased before starting this study. The serum samples collected before this study were anonymized in a fashion preventing any link with the patients' identification and their analysis approved on that condition by Sagamihara Hospital Research Ethics Committee. This study was conducted in accordance with the principles expressed in the Declaration of Helsinki.

Biomarker immunoassay
---------------------

RayBio human cytokine antibody array (RayBiotech, Norcross, GA) was used for detection of 274 biomarkers in pooled sera of two states, AoDILD and stable, according to the manufacturer's protocol. The Bio-Plex suspension array system (Bio-rad, Hercules, CA) was used for detection of biomarkers in individual sera from patients in the two different states, without pooling. Fluorokine MAP multiplex kits (R&D Systems, Minneapolis, MN) were used for detection of TIMP-1, TIMP-2, TIMP-3, and TIMP-4. Milliplex map kits (Millipore, Billerica, MA) were used for detection of transforming growth factor (TGF)-β1, TGF-β2, TGF-β3, leptin, osteopontin, and insulin. Procarta cytokine plex kits (Affymetrix, Santa Clara, CA) were used for detection of MMP-3, MMP-9, epidermal growth factor (EGF), (IL)-17F, IL-1α, IL-1 receptor antagonist (IL-1RA), IL-2, IL-2 receptor α (IL-2Rα), IL-6, Fas, Fas ligand (FasL), tumor necrosis factor (TNF)α, MMP-1, MMP-12, MMP-7, MMP-13, MMP-8, leukaemia inhibitory factor (LIF), and migration inhibitory factor (MIF).

Statistical analysis
--------------------

Differences in patient characteristics were analyzed by Mann-Whitney U test or Fisher's exact test using 2×2 contingency tables. Wilcoxon signed-rank test or Mann-Whitney U test was performed in the comparison of laboratory findings and biomarker assay results. It was defined statistical significance as *P* \< 0.05.

Results
=======

Characteristics of collagen disease patients with AoDILD
--------------------------------------------------------

In 84% (n = 21) of the patients with AoDILD, underlying CVD-ILD had been detected prior to the onset of AoDILD. Mortality of patients during the AoDILD state was 44% (n = 11). Lactate dehydrogenase, blood urea nitrogen, KL-6, and surfactant protein-D (SP-D) were more increased in AoDILD than in the stable state (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Albumin was decreased in the AoDILD state compared to these patients in the stable state.

Biomarker immunoassay
---------------------

Sera were pooled from 25 collagen disease patients in each state, i.e. stable and AoDILD. We assessed the presence of 274 biomarkers in these two pooled sera. Eighteen of them were found to be present at less than 0.67 times the level in the pooled sera at AoDILD compared to the stable state (Additional file [2](#S2){ref-type="supplementary-material"}: Table S2). Five biomarkers were present in AoDILD sera at levels more than 1.5 times the stable state. In addition to these 23 up-regulated or down-regulated biomarkers, several biomarkers were included from the results of previous studies on IPF or ARDS for candidates of further analysis \[[@B4],[@B6],[@B10]-[@B18]\]. Thirty one biomarkers were selected based on the availability of bead-based immunoassay for more detailed analysis. Up-regulated soluble TNF receptor II in this pooled assay would be derived from the administered recombinant soluble TNF receptor II-Fc fusion protein, etanercept. Because administration of antibody or recombinant cytokine receptors skews the cytokine profile \[[@B19]\], sera from the 2 RA patients treated with etanercept were excluded from the following individual biomarker analysis. The serum biomarker levels of the 23 collagen disease patients in the stable state and at AoDILD without pooling are shown in Table [1](#T1){ref-type="table"} and Additional file [3](#S3){ref-type="supplementary-material"}: Figure S1. Serum TIMP-1, osteopontin, IL-1RA, IL-2Rα, IL-6, and MMP-1 levels were significantly increased in the AoDILD state (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}A), whereas TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The ratio of MMP-3 to MMP-1 was reduced in the AoDILD state in these patients.

###### 

Biomarker levels in individual serum without pooling from collagen disease patients in the stable and AoDILD states

  **Biomarker (pg/ml)**     **Stable**                 **AoDILD**                 ***P***
  ----------------------- ------------ ------------- ------------ ------------- ---------
  TIMP-1                        207843     \(57972\)       285600     \(98476\)     0.015
  TIMP-2                        121481     \(22995\)       101922     \(18568\)     0.006
  TIMP-3                         15662     \(11925\)        15653      \(7974\)     0.196
  TIMP-4                          2908       \(941\)         2874       \(837\)     0.906
  MMP-3                         854165    \(668239\)       499442    \(312919\)     0.010
  MMP-9                        2615399   \(1577133\)      2837226   \(1619793\)     0.563
  TGF-β1                         57391     \(12908\)        52821     \(16415\)     0.101
  TGF-β2                          2475       \(889\)         2201       \(997\)     0.101
  TGF-β3                             0         \(0\)            0         \(0\)     1.000
  Leptin                          6424      \(6663\)         6275      \(8249\)     0.670
  Osteopontin                    14603     \(12657\)        30216     \(33636\)     0.012
  Insulin                          633       \(475\)          589       \(330\)     0.961
  EGF                              131       \(124\)          130       \(189\)     0.355
  Eotaxin2                        4497      \(3166\)         4223      \(5065\)     0.018
  Eotaxin3                          44        \(71\)           37        \(52\)     0.625
  IL-17 F                          125       \(340\)          168       \(519\)     0.761
  IL-1α                             61       \(248\)          137       \(607\)     1.000
  IL-1RA                           156       \(330\)          401       \(490\)     0.049
  IL-2                              41       \(121\)           77       \(246\)     0.427
  IL-2Rα                          3623      \(2134\)         7469      \(6483\)     0.001
  IL-6                             103       \(234\)          363       \(794\)     0.035
  Fas                             2237      \(9967\)         3450     \(13337\)     0.715
  FasL                              68        \(63\)           74        \(74\)     0.763
  TNFα                             841      \(1953\)         1052      \(2676\)     0.821
  MMP-1                          69662     \(86194\)        75510     \(58379\)     0.016
  MMP-12                          4992     \(14919\)         7406     \(23641\)     0.500
  MMP-7                           5874      \(5153\)         7871     \(11084\)     0.627
  MMP-13                         37860     \(74534\)        52019    \(111830\)     0.754
  MMP-8                          25817     \(17712\)        48700     \(54791\)     0.144
  LIF                               57       \(150\)          121       \(353\)     0.441
  MIF                            17352     \(34236\)        23178     \(29813\)     0.136
  MMP-3/MMP-1                    22.04       (18.56)        15.00       (19.61)    0.0208

AoDILD: acute-onset diffuse interstitial lung disease. Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Wilcoxon signed-rank test.

![**Biomarker profile of acute-onset diffuse interstitial lung disease (AoDILD).** Increased and decreased biomarkers in AoDILD state of collagen disease and rheumatoid arthritis (RA) patients were indicated in **A**. Increased and decreased biomarkers in AoDILD state of acute exacerbation of ILD (AE-ILD) and drug-induced interstitial lung disease (DI-ILD) patients were indicated in **B**. Increased and decreased biomarkers in AoDILD state of patients who subsequently died and those who survived were indicated in **C**.](1471-2172-14-9-1){#F1}

Serum biomarker profile of the RA patients with AoDILD
------------------------------------------------------

We next explored biomarkers associated with AoDILD in the patients with RA. Characteristics of the RA patients (n = 18) are compared with that of collagen disease patients (n = 23) in Additional file [4](#S4){ref-type="supplementary-material"}: Table S3. The laboratory findings of the RA patients in the stable state and in the AoDILD state are shown in Table [2](#T2){ref-type="table"}. KL-6, SP-D, and lactate dehydrogenase were increased in AoDILD of patients with RA. Albumin was decreased in AoDILD of patients with RA.

###### 

Laboratory findings and serum biomarker levels of the RA patients in stable and AoDILD states

                                      **RA patients (n = 18)**                     
  ----------------------------------- -------------------------- ----------------- --------
  White Blood Cell count(X1000/ml)    10.5 (3.8)                 12.1 (3.4)        0.1578
  Red Blood Cell count(X10^6^/ml)     4.2 (0.5)                  4.1 (0.6)         0.8506
  Hemoglobin(g/dl)                    12.6 (2.0)                 12.3 (1.8)        0.6378
  Hematocrit(%)                       39.4 (5.5)                 37.4 (5.3)        0.4703
  Platelet(X1000/ml)                  304.1 (121.2)              285.9 (108.4)     0.7064
  Albumin(g/dl)                       3.9 (0.4)                  3.2 (0.6)         0.0052
  Aspartate Aminotransferase(IU/l)    32.6 (39.8)                38.6 (27.2)       0.1167
  Alanine Aminotransferase(IU/l)      28.0 (36.3)                26.4 (28.8)       0.8068
  Lactate Dehydrogenase(IU/l)         224.7 (39.1)               371.8 (143.4)     0.0052
  Alkaline Phosphatase(IU/l)          275.4 (129.1)              260.4 (93.3)      0.9721
  γ-glutamyltransferase(IU/l)         33.5 (25.4)                110.9 (309.5)     0.1361
  Creatinine(mg/dl)                   0.6 (0.1)                  0.7 (0.2)         0.3627
  Blood Urea Nitrogen(mg/dl)          14.2 (2.8)                 17.3 (4.6)        0.1005
  C-reactive protein(mg/dl)           3.6 (3.6)                  11.1 (9.3)        0.1094
  KL-6(IU/ml)                         447.9 (244.3)              829.2 (473.8)     0.0052
  Surfactant Protein-D (SP-D)(U/ml)   74.1 (51.1)                169.3 (148.0)     0.0157
  TIMP-1(pg/ml)                       196945 (49413)             302152 (102113)   0.0071
  TIMP-2(pg/ml)                       117585 (23704)             99258 (16673)     0.0231
  MMP-3(pg/ml)                        910356 (732400)            451701 (312564)   0.0057
  Osteopontin(pg/ml)                  17095 (13228)              36200 (35682)     0.0198
  Eotaxin2(pg/ml)                     4482 (3387)                3308 (4017)       0.0108
  IL-1RA(pg/ml)                       187 (365)                  401 (359)         0.0759
  IL-2Rα(pg/ml)                       3842 (2128)                8624 (6810)       0.0025
  IL-6(pg/ml)                         123 (260)                  383 (852)         0.1119
  MMP-1(pg/ml)                        81755 (93582)              87509 (60314)     0.0582
  MMP-8(pg/ml)                        28379 (17114)              55764 (59399)     0.1841
  MMP-3/MMP-1                         20.66 (20.57)              12.83 (20.91)     0.0249

RA: rheumatoid arthritis, AoDILD: Acute-onset diffuse interstitial lung disease. Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Wilcoxon signed-rank test.

While the serum TIMP-1, osteopontin, and IL-2Rα levels were increased in patients with RA in the AoDILD state (Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}A), TIMP-2, MMP-3, and eotaxin 2 were decreased. The ratio of MMP-3 to MMP-1 was also reduced in the AoDILD state in these patients. These biomarker profiles were similar to that of collagen disease patients with AoDILD.

Serum biomarker profile of the patients with AE-ILD or DI-ILD
-------------------------------------------------------------

We also explored biomarkers associated with AoDILD in the patients with AE-ILD or DI-ILD. Characteristics of the AE-ILD (n = 9) and DI-ILD patients (n = 14) are shown in Additional file [5](#S5){ref-type="supplementary-material"}: Table S4. The laboratory findings of the patients with AE-ILD or DI-ILD in the stable state and in the AoDILD state are shown in Table [3](#T3){ref-type="table"}. KL-6 was increased in AoDILD of patients with AE-ILD. Albumin and hematocrit were decreased in AoDILD of patients with AE-ILD. KL-6 and lactate dehydrogenase were increased in AoDILD of patients with DI-ILD.

###### 

Laboratory findings and serum biomarker levels of collagen disease patients with AE-ILD or DI-ILD in stable and AoDILD states

                                      **AE-ILD (n = 9)**                                **DI-ILD (n = 14)**                        
  ----------------------------------- -------------------- ------------------- -------- --------------------- ------------------- --------
  White Blood Cell count (X1000/ml)   10.9 (2.7)           11.8 (2.6)          0.2135   10.3 (4.0)            12.1 (3.8)          0.2604
  Red Blood Cell count (X10^6^/ml)    4.2 (0.9)            4.4 (0.7)           0.9528   4.2 (0.5)             4.1 (0.6)           0.5536
  Hemoglobin (g/dl)                   13.4 (1.2)           12.7 (2.5)          0.2936   12.6 (2.3)            12.2 (1.9)          0.5147
  Hematocrit (%)                      42.1 (3.1)           38.9 (6.4)          0.0152   38.9 (6.4)            36.9 (5.9)          0.9528
  Platelet (X1000/ml)                 280.3 (58.0)         299.5 (110.0)       0.3139   318.2 (139.3)         293.5 (118.8)       0.8590
  Albumin (g/dl)                      4.1 (0.3)            3.6 (0.7)           0.0077   3.9 (0.4)             3.2 (0.6)           0.0687
  Aspartate Aminotransferase (IU/l)   41.2 (47.9)          44.4 (32.4)         0.6784   23.2 (4.6)            31.8 (13.6)         0.1282
  Alanine Aminotransferase (IU/l)     36.6 (43.2)          39.0 (36.2)         0.4838   19.7 (6.8)            18.0 (6.0)          0.6784
  Lactate Dehydrogenase (IU/l)        250.7 (45.3)         311.6 (86.2)        0.1386   215.2 (23.8)          383.6 (158.3)       0.0209
  Alkaline Phosphatase (IU/l)         278.1 (141.2)        239.3 (97.9)        0.7794   243.8 (89.5)          261.8 (90.2)        0.9528
  γ-glutamyltransferase (IU/l)        52.2 (44.4)          179.5 (392.2)       0.1551   26.3 (18.0)           31.1 (14.9)         0.4990
  Creatinine (mg/dl)                  0.7 (0.1)            0.7 (0.1)           0.8127   0.6 (0.1)             0.7 (0.2)           0.8127
  Blood Urea Nitrogen (mg/dl)         13.9 (2.3)           17.1 (6.2)          0.1097   14.4 (3.1)            16.8 (3.5)          0.4008
  C-reactive protein (mg/dl)          2.1 (2.3)            6.4 (10.1)          0.1097   3.9 (4.1)             11.2 (7.7)          0.2135
  KL-6 (U/ml)                         2078.1 (2525.4)      2105.8 (2495.5)     0.0280   431.0 (256.6)         799.7 (425.9)       0.0208
  Surfactant Protein-D (ng/ml)        160.7 (126.5)        194.7 (123.2)       0.1763   76.4 (53.5)           170.5 (163.6)       0.0619
  TIMP-1 (pg/ml)                      192899 (54474)       245030 (93165)      0.3105   218303 (58054)        313999 (91931)      0.0166
  TIMP-2 (pg/ml)                      123534 (24219)       100422 (12693)      0.1763   120044 (21985)        102973 (21694)      0.0125
  TIMP-3 (pg/ml)                      16813 (5411)         18791 (9923)        0.7353   14857 (14822)         13457 (5240)        0.1097
  MMP-3 (pg/ml)                       587882 (245290)      628244 (328962)     0.5940   1025348 (787427)      416640 (271619)     0.0019
  MMP-9 (pg/ml)                       2852316 (1698909)    2800269 (1205613)   0.5940   2463095 (1473636)     2860985 (1837002)   0.5509
  Osteopontin (pg/ml)                 12464 (10678)        28442 (35397)       0.0663   15979 (13604)         31356 (32402)       0.0736
  Eotaxin2 (pg/ml)                    3953 (2312)          5311 (5724)         0.3139   4846 (3566)           3523 (4453)         0.0258
  IL-1RA (pg/ml)                      94 (111)             417 (653)           0.0796   196 (409)             390 (346)           0.2209
  IL-2Rα (pg/ml)                      2611 (1669)          3689 (2047)         0.0506   4274 (2147)           9899 (7159)         0.0076
  IL-6 (pg/ml)                        37 (47)              238 (422)           0.0209   145 (290)             444 (952)           0.2455
  MMP-1 (pg/ml)                       26532 (18626)        44551 (43273)       0.1097   97389 (100090)        95411 (58164)       0.0962
  MMP-8 (pg/ml)                       24640 (18134)        49581 (74715)       0.3743   26573 (17394)         48134 (36641)       0.1401
  MMP-3/MMP-1                         29.78 (16.71)        29.11 (24.88)       0.7671   17.07 (17.98)         5.92 (4.81)         0.0043

AoDILD: Acute-onset diffuse interstitial lung disease, AE-ILD: acute exacerbation of interstitial lung disease, DI-ILD: drug-induced interstitial lung disease. Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Wilcoxon signed-rank test.

The serum IL-6 level was significantly increased in patients with AE-ILD in the AoDILD state (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}B). While the serum TIMP-1 and IL-2Rα levels were significantly increased in patients with DI-ILD in the AoDILD state (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}B), TIMP-2, MMP-3, and eotaxin 2 were decreased. The ratio of MMP-3 to MMP-1 was also reduced in the AoDILD state in these patients. These skewed biomarker profiles suggest differences in the pathogenesis of AoDILD in patients with AE-ILD or DI-ILD.

Association of serum biomarker profile with outcome
---------------------------------------------------

The characteristics of 23 collagen disease patients with AoDILD are shown in Additional file [6](#S6){ref-type="supplementary-material"}: Table S5. There were no significant differences between those who died and those who survived. KL-6 and SP-D were increased and red blood cell count, hemoglobin, and hematocrit were decreased in the AoDILD state of patients who died (n = 9, Table [4](#T4){ref-type="table"}). Lactate dehydrogenase, blood urea nitrogen and KL-6 were increased and albumin decreased in the AoDILD state in patients who survived (n = 14). TIMP-3, MMP-9, osteopontin, IL-2Rα, MMP-1, and MMP-8 levels were significantly increased in the AoDILD state in the deceased patients. The ratio of MMP-3 to MMP-1 was decreased in the AoDILD state in the deceased patients (Table [4](#T4){ref-type="table"}, Figure [1](#F1){ref-type="fig"}C). On the other hand, the serum TIMP2 and MMP-3 levels were decreased in the AoDILD state in patients who survived. Thus, biomarker profiles were different in patients with different outcomes.

###### 

Laboratory findings and serum biomarker levels of collagen disease patients with different clinical outcome in stable and AoDILD states

                                     **Died (n = 9)**                                **Survived (n = 14)**                        
  ---------------------------------- ------------------- ------------------- ------- ----------------------- ------------------- -------
  White Blood Cell count(X1000/ml)   8.5 (1.7)           10.4 (1.8)          0.138   11.4 (3.6)              13.0 (3.7)          0.279
  Red Blood Cell count(X10^6^/ml)    4.3 (0.3)           3.9 (0.7)           0.043   4.1 (0.8)               4.4 (0.6)           0.069
  Hemoglobin(g/dl)                   13.7 (1.2)          11.7 (2.7)          0.043   12.7 (2.0)              12.9 (1.7)          0.108
  Hematocrit(%)                      41.5 (3.5)          35.6 (6.7)          0.043   40.1 (5.8)              39.2 (5.4)          0.917
  Platelet(X1000/ml)                 266.0 (62.5)        310.1 (131.2)       0.281   312.1 (119.0)           287.1 (102.4)       0.972
  Albumin(g/dl)                      3.9 (0.2)           3.0 (0.6)           0.068   4.1 (0.5)               3.6 (0.5)           0.005
  Aspartate Aminotransferase(IU/l)   54.2 (60.6)         43.3 (34.2)         0.893   23.8 (6.8)              33.5 (14.0)         0.068
  Alanine Aminotransferase(IU/l)     47.0 (55.2)         34.1 (38.9)         0.500   20.8 (7.8)              22.6 (11.1)         0.480
  Lactate Dehydrogenase(IU/l)        234.0 (32.2)        361.8 (92.8)        0.138   232.5 (43.0)            346.2 (158.2)       0.039
  Alkaline Phosphatase(IU/l)         320.2 (169.8)       224.9 (67.2)        0.144   238.2 (82.4)            268.5 (103.1)       0.221
  γ-glutamyltransferase(IU/l)        42.4 (32.7)         179.1 (413.2)       0.419   38.1 (37.5)             42.8 (44.2)         0.142
  Creatinine(mg/dl)                  0.7 (0.1)           0.7 (0.2)           0.419   0.7 (0.1)               0.7 (0.1)           0.422
  Blood Urea Nitrogen(mg/dl)         13.1 (2.5)          15.1 (5.2)          0.715   14.5 (2.7)              18.1 (4.3)          0.039
  C-reactive protein(mg/dl)          0.8 (0.5)           12.0 (8.6)          0.080   3.8 (3.7)               7.3 (9.0)           0.311
  KL-6(U/ml)                         1364.1 (2423.4)     1565.4 (2498.4)     0.025   837.5 (936.0)           1173.8 (898.0)      0.017
  Surfactant Protein-D(ng/ml)        136.8 (125.6)       196.0 (114.4)       0.036   87.1 (60.4)             169.6 (167.8)       0.203
  TIMP-1(pg/ml)                      231906 (68528)      346576 (72337)      0.080   197816 (49624)          260193 (96764)      0.084
  TIMP-2(pg/ml)                      118406 (27648)      105669 (20160)      0.345   122762 (20616)          100361 (17629)      0.012
  TIMP-3(pg/ml)                      10668 (6632)        15759 (12498)       0.043   17743 (12977)           15609 (4998)        0.790
  MMP-3(pg/ml)                       752633 (495718)     513110 (247738)     0.214   919436 (751496)         490655 (348157)     0.030
  MMP-9(pg/ml)                       1769108 (1012232)   3358493 (1977141)   0.011   3159443 (1634403)       2502127 (1229009)   0.140
  Osteopontin(pg/ml)                 13588 (9212)        51660 (44658)       0.008   15256 (14407)           16430 (9537)        0.551
  Eotaxin 2(pg/ml)                   4854 (4321)         4320 (5943)         0.110   4267 (2079)             4160 (4408)         0.096
  IL-1RA(pg/ml)                      224 (463)           657 (559)           0.086   112 (190)               236 (352)           0.445
  IL-2Rα(pg/ml)                      3827 (2213)         8408 (4328)         0.011   3492 (2072)             6865 (7488)         0.064
  IL-6(pg/ml)                        156 (339)           710 (1157)          0.066   69 (115)                140 (222)           0.328
  MMP-1(pg/ml)                       35772 (19709)       73909 (39388)       0.011   91449 (103647)          76538 (67816)       0.397
  MMP-8 (pg/ml)                      14814 (12583)       51014 (40613)       0.008   32889 (16905)           47213 (62177)       0.826
  MMP-3/MMP-1                        23.67 (18.54)       10.29 (8.39)        0.028   21.00 (18.50)           18.02 (23.73)       0.221

AoDILD: Acute-onset diffuse interstitial lung disease. Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Wilcoxon signed-rank test.

Discussion
==========

Many studies have reported on biomarker profiles in IPF or ARDS patients \[[@B4]-[@B6]\]. The roles of MMPs and TIMPs in IPF or ARDS have been reported \[[@B10]-[@B12]\]. Involvement of other biomarkers in IPF or ARDS, including osteopontin \[[@B13]\], eotaxin 2 (CCL24) \[[@B14]\], IL-1RA \[[@B15],[@B16]\], IL- 2Rα \[[@B17]\], and IL-6 \[[@B18]\], were also inferred. The present study reports novel biomarker profiles of AoDILD occurring in collagen disease patients, though a few of these biomarkers have been analyzed previously in such patients with chronic CVD-ILD \[[@B20],[@B21]\]. Administration of the cytokines found to be decreased, or blocking cytokines found to be increased with antibodies or inhibitors could represent new therapeutic approaches for AoDILD in collagen disease patients \[[@B22]\].

We also propose that serum biomarker patterns could represent prognostic markers for AoDILD in collagen diseases. Several studies reported that the expression of MMP-1 and MMP-3 by fibroblasts and chondrocytes was correlated \[[@B12],[@B23]\]. This was measured as the ratio of MMP-3 to MMP-1 and was maintained in the sera of patients who survived, but not in those who died (Table [4](#T4){ref-type="table"}, Figure [1](#F1){ref-type="fig"}C). Similarly, different biomarker profiles were seen in deceased and surviving patients. These biomarkers were up-regulated in the sera of the patients with AoDILD who died (TIMP-3, MMP-9, osteopontin, IL-2Rα, MMP-1, and MMP-8, Figure [1](#F1){ref-type="fig"}C) or down-regulated in the sera of the patients with AoDILD who survived (TIMP2 and MMP-3). These biomarker molecules might accelerate the progress of AoDILD and could be targets blocked with antibodies or inhibitors for the treatment. Since there were no oppositely regulated biomarker molecules, we could not find any molecules that might prevent the progress of AoDILD. Role of other molecules in the pathological state of AoDILD, such as TIMP-1, eotaxin 2, IL-1RA, or IL-6 could not be estimated in this study. Thus, the MMP-3 to MMP-1 ratio, and levels of TIMP-3, MMP-9, and osteopontin could be prognostic markers for AoDILD in collagen diseases.

The serum osteopontin (*P* = 0.0233, Mann-Whitney U test), IL-1RA (*P* = 0.0350), and IL-6 (*P* = 0.0320) levels were higher in patients who died in the AoDILD state, compared with those who survived (Table [4](#T4){ref-type="table"}). The serum MMP-9 (*P* = 0.0376, Mann-Whitney U test) and MMP-8 (*P* = 0.0167) levels were higher in patients who survived in the stable state, compared with those who died (Table [4](#T4){ref-type="table"}). These data suggest that some biomarkers could represent prognosis of the patients with AoDILD, without comparison of the paired serum levels between stable and AoDILD states.

The ratio of MMP-3 to MMP-1 was maintained in the sera of AE-ILD patients (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}B). However, the correlation was no longer present in DI-ILD patients (Table [3](#T3){ref-type="table"}). In addition, serum profiles of eotaxin 2 and MMP-3 were completely different in patients with AE-ILD and DI-ILD. The serum IL-2Rα, (*P* = 0.0406, Mann-Whitney U test) and MMP-1 (*P* = 0.0140) levels were higher in patients with DI-ILD in the AoDILD state, compared with those with AE-ILD (Table [3](#T3){ref-type="table"}). The ratio of MMP-3 to MMP-1 was lower in patients with DI-ILD in the AoDILD state, compared with those with AE-ILD (*P* = 0.0068, Table [3](#T3){ref-type="table"}). The serum MMP-1 (*P* = 0.0016, Mann-Whitney U test) level was higher in patients with DI-ILD in the stable state, compared with those with AE-ILD (Table [3](#T3){ref-type="table"}). Thus, our findings suggest the possibility of different pathogenesis of AE-ILD and DI-ILD. Because of the limited sample size of this study, the expression pattern of these biomarkers needs to be confirmed in future studies.

Conclusions
===========

To our knowledge, this is the first report of biomarker profiling in AoDILD occurring in collagen disease patients. Our findings support the role of serum biomarker profiles as prognosis markers for AoDILD.
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